TheEdgeResearch
Home / Stocks / TWAPF

Towa Pharmaceutical Co., Ltd. (TWAPF)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$25.98 ▲ +0.00%
Market Cap
$1.28B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
-0.09
52-Wk Range
16.83-26
CEO
Itsuro Yoshida
Country
JP
Currency
USD

Towa Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Osaka, JP. The stock last traded at $25.98, up 0.00% on the session, giving a market capitalisation of $1.28B. On trailing twelve-month figures it carries a trailing P/E of 22.03, a net margin of 3.0%. Its beta of -0.09 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
22.03
Price / Sales
0.65
Price / Book
1.00
EV / EBITDA
9.22
Gross margin
36.3%
Operating margin
8.7%
Net margin
3.0%
Return on equity
Debt / equity
1.26
Current ratio
2.82
Dividend yield
2.2%
Payout ratio
47.7%
Company profile
Exchange
Other OTC
Employees
4,923
IPO date
2009-10-21
Headquarters
Osaka, JP
About Towa Pharmaceutical Co., Ltd.

Operating in Japan, Towa Pharmaceutical Co., Ltd. and its subsidiaries are engaged in the research, development, production, and sale of prescription drugs, active pharmaceutical ingredients, and intermediates. The company's extensive portfolio addresses critical therapeutic areas such as diabetes, digestive health, neurological conditions, and allergic diseases, alongside offering vitamins, antibiotics, and oncology treatments. With approximately 700 different drug products, Towa Pharmaceutical Co., Ltd. was established in 1951 and is headquartered in Osaka, Japan.

Comparable companies

Towa Pharmaceutical Co., Ltd. is most often compared with the following Healthcare names:

BIOGYCHIZFEVOTFGNMLFKSPHFLJUIFNPNKFNPPNYSWGHFTCNNF
More research on TWAPF
TWAPF technical analysis TWAPF TheEdge Score Compare against peers
Open full interactive analysis & DCF →